TabletsClinical Overview
Gliclazide (Modified Release 30 mg, 60 mg) is a second-generation oral sulfonylurea with selective pancreatic tropism on the WHO Model List of Essential Medicines. It selectively binds to SUR1 receptors with fast reversible kinetics, restoring early first-phase insulin secretion and protecting vascular endothelium against oxidative stress via free radical-scavenging properties. Modified-release tablets provide steady 24-hour glycemic coverage with low hypoglycemia and weight gain risk. Indicated for type 2 diabetes mellitus in adults.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily as a single dose with breakfast with water. Swallow tablets whole; do not break, chew, or crush. Must be taken with food.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Mild hypoglycemia, dyspepsia, abdominal pain, nausea, constipation. Rare/Severe: Severe hypoglycemia, allergic skin reactions, and hepatic enzyme elevation.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Do not skip meals after taking. Contraindicated in type 1 diabetes, ketoacidosis, and severe renal or hepatic failure. Monitor blood glucose regularly.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered endocrinologist, diabetologist, or qualified physician before initiating, adjusting dosages of, or substituting any antidiabetic or hormonal medication.
Gliclazide Tablets 80 mg
Gliclazide (Modified Release 30 mg, 60 mg) is a second-generation oral sulfonylurea with selective pancreatic tropism on the WHO Model List of Essential Medicines. It selectively binds to SUR1 receptors with fast reversible kinetics, restoring early first-phase insulin secretion and protecting vascular endothelium against oxidative stress via free radical-scavenging properties. Modified-release tablets provide steady 24-hour glycemic coverage with low hypoglycemia and weight gain risk. Indicated for type 2 diabetes mellitus in adults.
Gliclazide Extended release Tablets 60 mg
Gliclazide (Modified Release 30 mg, 60 mg) is a second-generation oral sulfonylurea with selective pancreatic tropism on the WHO Model List of Essential Medicines. It selectively binds to SUR1 receptors with fast reversible kinetics, restoring early first-phase insulin secretion and protecting vascular endothelium against oxidative stress via free radical-scavenging properties. Modified-release tablets provide steady 24-hour glycemic coverage with low hypoglycemia and weight gain risk. Indicated for type 2 diabetes mellitus in adults.
Gliclazide 80mg + Metformin Hydrochloride 500mg Tablets
Metformin Hydrochloride and Gliclazide (Modified Release) combines an insulin sensitizer with a selectively reversible sulfonylurea. Gliclazide selectively binds to pancreatic beta-cell SUR1 receptors with fast on-off association kinetics, restoring the physiological first-phase insulin secretory burst and offering lower hypoglycemia risk than glibenclamide, while metformin reduces hepatic glucose output. Indicated for type 2 diabetes mellitus when monotherapy provides insufficient glycemic control.
Gliclazide 60mg (Modified Release) + Metformin 500mg (Extended Release) Tablets
Metformin Hydrochloride and Gliclazide (Modified Release) combines an insulin sensitizer with a selectively reversible sulfonylurea. Gliclazide selectively binds to pancreatic beta-cell SUR1 receptors with fast on-off association kinetics, restoring the physiological first-phase insulin secretory burst and offering lower hypoglycemia risk than glibenclamide, while metformin reduces hepatic glucose output. Indicated for type 2 diabetes mellitus when monotherapy provides insufficient glycemic control.